More on J&J's (JNJ) Q2: Net profit falls to $1.41B from $2.78B; Q2 2012 includes special...


More on J&J's (JNJ) Q2: Net profit falls to $1.41B from $2.78B; Q2 2012 includes special items of $2.2B, comprising a write-down related to J&J's Crucell (CRXL) vaccine ops, provision for litigation, costs connected to Synthes acquisition. Cuts 2012 EPS outlook to $5.00-$5.07 from up to $5.17. Consensus is $5.14. Shares -1.4%. (PR)

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs